Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

An artificial intelligence-aided program accurately predicted 5-year survival for early breast cancer on the basis of a tumor's location. (JCO Clinical Cancer Informatics) Actor D ...

BeiGene ends its Phase 3 lung cancer trial for ociperlimab after a futility analysis. No new safety concerns were found, and study results will be shared later.

Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a ...

A key lung cancer congress held in Europe disclosed that a new breakthrough has been made by Hengrui Pharmaceuticals, a ...

New research delves into the DNA details and chromatin structures that may predict prognosis in early-stage lung ...

In accordance with the NMPA approval, Gyre intends to pursue an adaptive Phase 2/3 clinical trial design, combining dose exploration with efficacy confirmation, to efficiently evaluate pirfenidone's ...

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding ...

Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat ...

In the growing field of personalized medicine, scientists at Yale University have found promising evidence that a simple ...

According to a Reuters report posted on March 25, Chinese ... and lung. Veracyte (NASDAQ:VCYT) shared new findings at EAU25 ...